LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LPCN
Lipocine Inc.
There isn't enough reported data to score LPCN yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LPCN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Unavailable | |
| Unavailable |
LPCN's revenue is currently stable, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LPCN PE Valuation
LPCN has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
LPCN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect LPCN's losses to shrink, with revenue declining.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over LPCN on earnings quality, reporting a profit while its opponent remains loss making.
LPCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.28 | -$0.27 |
| Q2 2026 | -$1.79 | -$0.93 |
| Q1 2026 | -$1.88 | -$0.87 |
| Q4 2025 | -$1.69 | -$1.69 |
| Q3 2025 | -$1.01 | +$0.48 |
| Q2 2025 | -$0.86 | +$1.45 |
| Q1 2025 | -$1.01 | +$1.42 |
| Q4 2024 | -$0.00 | +$3.77 |
LPCN is still losing money, but far less than before: $1.28 per share over the past year, against $8.50 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LPCN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LPCN on profitability, with a higher operating margin.
LPCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3M | +1899% |
| Q2 2026 | $190.1K | -69% |
| Q1 2026 | $119.4K | +27% |
| Q4 2025 | $1.1M | -67% |
| Q2 2025 | $622.8K | +595% |
| Q1 2025 | $93.9K | -99% |
| Q4 2024 | $3.5M | +1515% |
| Q1 2024 | $7.6M | +13752% |
LPCN's revenue is recovering but still below its 2021 peak: $2M last quarter, up 1899% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -38% | +2896 points |
| Q2 2026 | -1495% | -1109 points |
| Q1 2026 | -3224% | -997 points |
| Q4 2025 | -220% | -264 points |
| Q3 2025 | -2934% | N/A |
| Q2 2025 | -386% | +3290 points |
| Q1 2025 | -2227% | -2269 points |
| Q4 2024 | 44% | +1244 points |
LPCN's operating margin was −38% last quarter, up 2896 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with LPCN at up 26%.
LPCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3M | -$1.1M |
| Q1 2026 | -$2.3M | -$287.9K |
| Q4 2024 | $1.7M | +$3.7M |
| Q4 2023 | -$2M | -$95.8K |
| Q3 2023 | -$2.6M | +$592.1K |
| Q2 2023 | -$3.3M | -$253K |
| Q1 2023 | -$3.9M | -$19.9K |
| Q3 2022 | -$3.2M | +$3.8M |
LPCN has burned cash in almost every quarter: −$9M over the past year, against −$5M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LPCN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LPCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +27.6K shares |
| 1 year | +54% | +2.9M shares |
| 3 years | +57% | +3M shares |
| 5 years | +59% | +3.1M shares |
| Available history | +239% | +5.8M shares |
LPCN has 8M diluted shares, up 54% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LPCN Net Leverage
LPCN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LPCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.9 | Neutral |
| Stochastic | 9.5 | Oversold |
LPCN's weekly RSI is 35 (neutral) and its Stochastic is 10 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LPCN PE vs Healthcare Sector
| Metric | LPCN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LPCN has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LPCN on trend strength, trading above more of its moving averages.
LPCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.69 | 4.1% below |
| 20 week MA | $2.01 | 19% below |
| 50 week MA | $3.99 | 59% below |
| 100 week MA | $3.69 | 56% below |
| 200 week MA | $4.28 | 62% below |
LPCN is in a downtrend: it's below all five of its weekly moving averages, and 62% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LPCN on returns for 2026, with the stronger performance.
LPCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.04 | $24.1 | +300% |
| 2021 | $24.1 | $18.0 | -25% |
| 2022 | $18.0 | $6.90 | -62% |
| 2023 | $6.90 | $2.79 | -60% |
| 2024 | $2.79 | $4.76 | +71% |
| 2025 | $4.76 | $5.23 | +9.9% |
| 2026 YTD | $5.23 | $1.62 | -69% |
LPCN's yearly returns have swung widely, from +300% in 2020 to −62% in 2022. It's down 69% so far in 2026.